• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Novartis

Novartis

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Resistant Hypertension - Pipeline Review, H2 2016 - Key Players are Bayer AG, Novartis AG , Sarfez Pharmaceuticals, PhaseBio Pharmaceuticals & Zumbro Discovery - Research and Markets

    Resistant Hypertension - Pipeline Review, H2 2016 - Key Players are Bayer AG, Novartis AG , Sarfez Pharmaceuticals, PhaseBio Pharmaceuticals & Zumbro Discovery - Research and Markets

  2. Graves Diseases - Pipeline Review, H2 2016 - Key Companies are Apitope International NV, Nova Therapeutics LLC, Novartis AG , Omeros Corp & Rodos BioTarget GmbH - Research and Markets

    Graves Diseases - Pipeline Review, H2 2016 - Key Companies are Apitope International NV, Nova Therapeutics LLC, Novartis AG , Omeros Corp & Rodos BioTarget GmbH - Research and Markets

  3. Human Growth Hormone (hGH) Market: Innovation in Drug Delivery System with Eli Lilly and Company, Novartis AG , Novo Nordisk & Pfizer Dominating - Research and Markets

    Human Growth Hormone (hGH) Market: Innovation in Drug Delivery System with Eli Lilly and Company, Novartis AG , Novo Nordisk & Pfizer Dominating - Research and Markets

  4. $11.04 Billion Next Generation Cancer Diagnostics Market 2017 By Technology, Application, Cancer Type, Function Companion Diagnostics - Forecasts to 2025 - Research and Markets

    $11.04 Billion Next Generation Cancer Diagnostics Market 2017 By Technology, Application, Cancer Type, Function Companion Diagnostics - Forecasts to 2025 - Research and Markets

  5. $52.37 Billion Pulmonary/ Respiratory Drug Delivery Market 2017 by Formulation, Device Type, Canister, End User, Applications - Forecasts to 2021 - Research and Markets

    $52.37 Billion Pulmonary/ Respiratory Drug Delivery Market 2017 by Formulation, Device Type, Canister, End User, Applications - Forecasts to 2021 - Research and Markets

  6. PharmaPoint: $26.71 Billion Non-Small Cell Lung Cancer (NSCLC) Market - Global Drug Forecast and Analysis to 2025 - Research and Markets

    PharmaPoint: $26.71 Billion Non-Small Cell Lung Cancer (NSCLC) Market - Global Drug Forecast and Analysis to 2025 - Research and Markets

  7. UPDATE: 5 reasons to invest in European stocks now

    UPDATE: 5 reasons to invest in European stocks now

  8. UPDATE: 5 reasons to invest in European stocks now

    UPDATE: 5 reasons to invest in European stocks now

  9. UPDATE: 5 reasons to invest in European stocks now

    UPDATE: 5 reasons to invest in European stocks now

  10. Rheumatoid Arthritis - Pipeline Review, H2 2016 - Key Vendors are A&G Pharmaceutica, Amgen, GlaxoSmithKline, Merck & Novartis - Research and Markets

    Rheumatoid Arthritis - Pipeline Review, H2 2016 - Key Vendors are A&G Pharmaceutica, Amgen, GlaxoSmithKline, Merck & Novartis - Research and Markets

12345

©2017 Morningstar Advisor. All right reserved.